Rock Springs Capital Management LP Acquires 29,987 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Rock Springs Capital Management LP grew its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 7.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 444,383 shares of the company’s stock after acquiring an additional 29,987 shares during the period. Rock Springs Capital Management LP’s holdings in Perspective Therapeutics were worth $1,418,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CATX. Y Intercept Hong Kong Ltd bought a new position in Perspective Therapeutics in the 4th quarter valued at approximately $33,000. Aigen Investment Management LP acquired a new position in Perspective Therapeutics during the fourth quarter worth $34,000. National Bank of Canada FI boosted its stake in Perspective Therapeutics by 549,900.0% during the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after purchasing an additional 10,998 shares during the last quarter. Vontobel Holding Ltd. bought a new stake in Perspective Therapeutics during the fourth quarter worth $51,000. Finally, Trueblood Wealth Management LLC raised its holdings in shares of Perspective Therapeutics by 37.0% in the fourth quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company’s stock valued at $71,000 after purchasing an additional 6,000 shares during the last quarter. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Stock Performance

CATX opened at $1.94 on Monday. The stock’s fifty day moving average is $2.39 and its two-hundred day moving average is $5.00. Perspective Therapeutics, Inc. has a 52 week low of $1.60 and a 52 week high of $19.05.

Analysts Set New Price Targets

CATX has been the subject of a number of research reports. Truist Financial reduced their target price on shares of Perspective Therapeutics from $21.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, April 7th. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. Finally, Royal Bank of Canada decreased their target price on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $12.75.

Insider Buying and Selling at Perspective Therapeutics

In other news, Director Robert F. Williamson III bought 22,192 shares of the business’s stock in a transaction that occurred on Friday, March 28th. The shares were purchased at an average cost of $2.27 per share, with a total value of $50,375.84. Following the transaction, the director now directly owns 70,837 shares in the company, valued at approximately $160,799.99. The trade was a 45.62 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Johan M. Spoor acquired 22,026 shares of the company’s stock in a transaction dated Friday, March 28th. The stock was acquired at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the acquisition, the chief executive officer now directly owns 59,383 shares in the company, valued at approximately $133,017.92. The trade was a 58.96 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 115,696 shares of company stock valued at $256,344. 3.52% of the stock is currently owned by insiders.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.